Short Interest in Ainos, Inc. (NASDAQ:AIMD) Drops By 79.8%

Posted by Francis Steltz on Jun 29th, 2026

Ainos, Inc. (NASDAQ:AIMD – Get Free Report) was the target of a significant drop in short interest in June. As of June 15th, there was short interest totaling 18,552 shares, a drop of 79.8% from the May 31st total of 91,823 shares. Based on an average trading volume of 66,646 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ainos has an average rating of “Sell”.

Check Out Our Latest Analysis on AIMD

Ainos Stock Performance

Shares of NASDAQ AIMD traded up $0.03 during trading hours on Monday, hitting $1.76. 4,130 shares of the company’s stock were exchanged, compared to its average volume of 506,130. The company’s 50-day moving average price is $1.90 and its 200-day moving average price is $1.79. Ainos has a 1-year low of $1.26 and a 1-year high of $4.50. The stock has a market capitalization of $15.04 million, a price-to-earnings ratio of -0.61 and a beta of 2.41. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.55 and a quick ratio of 0.50.

Ainos (NASDAQ:AIMD – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter. Ainos had a negative return on equity of 160.55% and a negative net margin of 11,912.10%.

Insider Buying and Selling at Ainos

In other news, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of Ainos stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $2.36, for a total transaction of $96,760.00. Following the completion of the sale, the insider directly owned 948,925 shares in the company, valued at $2,239,463. The trade was a 4.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Chun-Jung Tsai sold 27,718 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $1.87, for a total value of $51,832.66. Following the completion of the transaction, the director owned 658,199 shares in the company, valued at $1,230,832.13. This represents a 4.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have bought 7,800 shares of company stock worth $15,946 and have sold 179,788 shares worth $359,247. Corporate insiders own 9.79% of the company’s stock.

Hedge Funds Weigh In On Ainos

Large investors have recently bought and sold shares of the stock. Mariner LLC bought a new stake in Ainos in the 4th quarter valued at $37,000. Renaissance Technologies LLC raised its position in shares of Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares during the last quarter. DRW Securities LLC lifted its stake in shares of Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after buying an additional 48,439 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in Ainos during the third quarter worth about $80,000.

About Ainos

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.